Last mentioned: Feb 23, 2026
Q4 Earnings Preview
Analysts project significant revenue growth from Amtagvi sales.
Commercial Expansion
Iovance scales ATC network to over 50 centers nationwide.
FDA Approval
Amtagvi receives accelerated approval for metastatic melanoma.
Iovance Biotherapeutics is set to report Q4 2025 results, with investors laser-focused on the commercial trajectory of Amtagvi, the first FDA-approved TIL therapy. The report will provide critical data on treatment center onboarding, patient enrollment, and the company's path toward profitability in the cell therapy space.
This page surfaces every story mentioning Amtagvi across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Amtagvi was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |